Ticker News
$WGRX News
Stored TradersLink news articles and press-release context for this ticker. Discord alerts link into these article pages when full article text is available.
Published Articles
Latest saved alerts
WGRX proposes rename to DataMeds AI (proposed ticker MEDS), rebrands pharmacy unit and targets Q3 2026 closing
Wellgistics Health (NASDAQ: WGRX) said its board selected DataMeds AI, Inc. as the proposed new corporate name (proposed ticker MEDS) and filed a preliminary proxy with the SEC seeking shareholder approval; it also will rebrand its Pharmacy division as Corexa Health while pursuing a proposed transaction with DataVault AI, Scilex, EOS and HealthBridge aimed at vertically integrating telemedicine, pharmacy, labs and wearables, targeted for completion in Q3 2026 subject to customary closing conditions. The company reports 2,647,198 common shares outstanding with ~1,333,930 shares locked up for at least 90 days, 919,465 shares deposited at DTCC available for trading, 80,826 cash warrants outstanding at a $35 strike, and no convertible debt or preferred equity currently eligible to convert to free-trading common shares.
WGRX: recent financing gives runway into late‑2026; lock-up leaves ~1.3M shares tradable; warrants could fund to 2029
Wellgistics says a recent capital raise and debt restructuring provides capital into late 2026, includes embedded warrants that, if exercised, would provide funding through 2029, and a lock-up limits freely tradable common shares to about 1.3 million. New shares from that financing will not be eligible for resale until issued and registered or eligible under Rule 144 (the company expects resale registration effectiveness in Q3 2026), and the company cannot issue shares for capital-raising until the earlier of seven months from the transaction date and 30 days after effectiveness of the resale registration statement. The company reiterated the DelivMeds AI and QOLPOM transactions are expected to close in Q3 2026 but remain subject to customary closing conditions. Timing: Public-market dilution depends on another filing or resale step first, and the press release does not say when that will be completed.
WGRX: Majority Shareholders Agree to 90‑Day Lock-Up on 1.33M Shares
Wellgistics (WGRX) said holders of 1,333,930 common shares — a majority of its outstanding common stock — agreed to a minimum 90‑day lock‑up preventing those shares from being sold into the market. The company said the lock-up, together with a recent restructuring of convertible liabilities and new funding, supports execution of its recently disclosed growth plan and temporarily removes a majority of shares from circulation, potentially reducing near‑term selling pressure while management pursues milestones.
WGRX: Holders of majority of shares agree to 90-day lock-up on 1.33M shares
Wellgistics Health said holders of 1,333,930 common shares — described as a majority of outstanding common stock — have agreed not to sell those shares into the market for at least 90 days. Management said the lock-up, together with a recent convertible-liability restructuring and new funding, supports execution of its growth plan and should reduce near-term sell pressure.
WGRX refinances convertibles with $21M note and raises $6.5M
Wellgistics (WGRX) issued a new $21M convertible debt instrument that refinanced all outstanding convertible debt and provided $6.5M in fresh capital; the offering was oversubscribed and the New Debt accrues no interest. The New Debt converts into common at $6.00 and contains an automatic exchange into a Funding Preferred (which itself converts into common at $50.00) upon registration effectiveness and shareholder approval; proceeds satisfy a closing condition for the company's DelivMeds AI transaction but the conversion mechanics may produce substantial future dilution.